renalna dislipidemija u bolesnika na kroničnoj hemodijalizi

V. Kova~i} i sur. Lipidi u kroni~noj hemodijalizi Lije~ Vjesn 2003; godi{te 125
disease outcomes in maintenance dialysis patients. Arterioscler Thromb
1997;17:2554–8.
13. Dierkes J, Domröe U, Ambrosch A, Bosselmann HP, Neumann KH, Luley
C. Response of hyperhomocysteinemia to folic acid supplementation in
patients with end-stage renal disease. Clin Nephrol 1999;51:108–15.
14. Bostom AG, Shemin D, Lapane KL, Hume AL, Yoburn D, Nadeau MR, Bendich
A, Selhub J, Rosenberg IH. High dose B-vitamin treatment of hyperhomocysteinemia
in dialysis patients. Kidney Int 1996;49:147–52.
15. Ma KW, Greene EL, Raij L. Cardiovascular risc factors in chronic renal
failure and hemodialysis populations. Am J Kidney Dis 1992;19:505–13.
16. Senti M, Romero R, Pedro-Bottet J, Pelegri A, Nogues X, Rubies-Prat J.
Lipoprotein abnormalities in hyperlipidemic and normolipidemic men
on hemodialysis with chronic renal failure. Kidney Int 1992;41:1394–9.
17. Joven J, Vilella E, Ahmad S, Cheung MC, Brunzell JD. Lipoprotein heterogenity
in end-stage renal disease. Kidney Int 1993;43:410–8.
18. Oda H, Yorioka N, Okushin S, Nishida Y, Kushihata S, Ito T i sur. Remnant-like
particles cholesterol may indicate atherogenic risk in patients
on chronic hemodialysis. Nephron 1997;76:7–14.
19. Zambon S, Zambon A, Stabellini N, Tarroni G, Gilli P, Crepaldi G i sur.
Lipoprotein abnormalities in hypertriglyceridemic patient on long-term
haemodialysis. J Intern Med 1993;234:217–21.
20. Samuelsson O, Attman PO, Knight-Gibson C, Kron B, Larsson R, Mulec
H i sur. Lipoprotein abnormalities without hyperlipidemia in moderate
renal insuffiency. Nephrol Dial Transplant 1994;9:1580–5.
21. Elisaf MS, Bairaktari HT, Tziallas CS, Germanos NK, Siamopoulos KC.
Atherogenic lipid and lipoprotein parameters in hemodialysis patients.
Dial Transplant 1995;24:642–60.
22. Moberly JB, Attman PO, Samuelsson O, Johansson AC, Knight-Gibson C,
Alaupovic P. Apolipoprotein C-III, hypertriglyceridemia and triglyceride-
-rich lipoproteins in uremia. Miner Electrolyte Metab 1999;25:258–62.
23. Tomura S, Nakamura Y, Doi M, Ando R, Ida T, Chida Y i sur. Fibrinogen,
coagulation factor VII, tissue plasminogen activator, plasminogen activator
inhibitor-1, and lipid as cardiovascular risk factors in chronic hemodialysis
and continuous ambulatory peritoneal dialysis patients. Am J Kidney
Dis 1996;27(6):848–54.
24. Attman PO, Knight-Gibson C, Tavella M, Samuelsson O, Alaupovic P.
The compositional abnormalities of lipoproteins in diabetic renal failure.
Nephrol Dial Transplant 1998;13:2833–41.
25. Shoji T, Nishizawa Y, Nishitani H, Yamakawa M, Morii H. Impaired metabolism
of high density lipoprotein in uremic patients. Kidney Int 1992;41:
1653–61.
26. Havel RJ, Hamilton RL. Hepatocytic lipoprotein receptors and intracellular
lipoprotein catabolism. Hepatology 1988;8:1689–704.
27. Querfeld U, Ong JM, Prehn J. Effects of cytokines on production of
lipoprotein lipase in cultured human macrophages. J Lipid Res 1990;31:
1379–86.
28. Attman PO, Alaupovic P. Lipid and apolipoprotein profiles of uremic
dyslipoproteinemia-relation to renal function and dialysis. Nephron 1991;
57:401–10.
29. Sakurai T, Oka T, Hasegawa H, Igaki N, Miki S, Goto T. Comparison of
lipids, apoproteins and associated enzyme activities between diabetic
and nondiabetic endstage renal disease. Nephron 1992;61:409–14.
30. Kamanna VS, Kashyap ML, Pai R. Uremic serum subfraction inhibits
apolipoprotein A-I production by human hepatoma cell line. J Am Soc
Nephrol 1994;5:193–200.
31. Deckelbaum RJ, Granot E, Oschry Y, Rose L, Eisenberg S. Plasma triglyceride
determines structure-composition in low- and high-density lipoproteins.
Arterioslerosis 1984;4:225–31.
32. O’Neal D, Lee P, Murphy B, Best J. Low-density lipoprotein particle size
distribution in end-stage renal disease treated with hemodialysis or peritoneal
dialysis. Am J Kidney Dis 1996;27:84–91.
33. Keane WF. Lipids and kidney. Kidney Int 1994;46:910–20.
34. Sutherland W, Walker RJ, Ball MJ, Stapley S, Robertson MC. Oxidation
of low-density lipoproteins from patients with renal failure or renal transplants.
Kidney Int 1995;48:227–36.
35. Maggi E, Bellazzi R, Falaschi F, Frattoni A, Perani G, Finardi G. Enhanced
LDL oxidation in uremic patient an additional mechanism for accelerated
atherosclerosis Kidney Int 1994;45:876–83.
36. Reiner Z, Tedeschi-Reiner E. Pathophysiology of atherosclerosis. The
morphology and developmental levels of atherosclerotic changes. Lije~
Vjesn 1990;112:118–23.
37. Elisaf M, Bairaktari H, Tzallas C, Germanos N, Koulouridis E, Pappas
M i sur. Lipid parameters including Lp(a) in hemodialysis patients. Renal
Failure 1994;16:501–9.
38. Attman PO, Alaupovic P, Tavella M, Knight-Gibson C. Abnormal lipid and
apolipoprotein composition of major lipoprotein density classes in patients
with chronic renal failure. Nephrol Dial Transplant 1996;11:63–9.
39. Cressman MD, Heyaka RJ, Paganini EP, O’Neil J, Skibinski CI, Hoff
HF. Lipoprotein(a) is an independent risk factor for cardiovascular disease
in hemodialysis patients. Circulation 1992;86:475–82.
40. Kandoussi AM, Hugue V, Cachera C, Hazzan M, Dracon M, Tacquet A i
sur. Apo(a) phenotypes and Lp(a) concentrations in renal transplant patients.
Nephron 1998;80(2):183–7.
41. Panzetta O, Cominacini L, Garbin U, Fratta Pasini A, Gammaro L, Bianco
F i sur. Increased susceptibility of LDL to in vitro oxidation in patients
on maintence hemodialysis: Effect of fish oil and vitamin E. Clin
Nephrol 1995;44:303–9.
42. Bartens W, Wanner C. Lipoprotein(a): New insights into an atherogenic
lipoprotein. Clin Invest 1994;72:558–67.
43. Walker RJ, Sutherland WHF, Walker HL, MacMahon S, Robson RA. Effect
of treatment with simvastatin on serum cholesteryl ester transfer in patients
on dialysis. Nephrol Dial Transplant 1997;12(1):87–92.
44. Gehr TWB, Sica DA, Slugg PH, Hammett JL, Raymond R, Ford NF. The
pharmacokinetics of pravastatin in patients on chronic hemodialysis. Eur
J Clin Pharmacol 1997;53(2):117–21.
45. Nishizawa Y, Shoji T, Emoto M, Kawasaki K, Konishi T, Tabata T i sur.
Reduction of intermediate density lipoprotein by pravastatin in hemoand
peritoneal dialysis patients. Clin Nephrol 1995;43:268–77.
46. Samuelsson O, Attman PO, Knight-Gibson C, Kron B, Larsson R, Mulec H
i sur. Effect of gemfibrozil on lipoprotein abnormalities in chronic renal
insuffiency. A controled study in human chronic renal disease. Nephron 1997;
75:286–94.
47. Nishikawa O, Mune M, Miyano M, Nishide T, Nishide I, Maeda A i sur.
Effect of simvastatin on lipid profile of hemodialysis patients. Kidney
Int Suppl 1999;71:219–21.
48. Thompson CH, Irish A, Kemp GJ, Taylor DJ, Radda GK. Skeletal muscle
metabolism before and after gemfibrozil treatment in dialysed patients
with chronic renal failure. Clin Nephrol 1996;45(6):386–9.
49. Elisaf M, Bairaktari E, Kaptopodis P, Pappas M, Sferopoulos G, Tziallas
C i sur. Effect of L-carnitine supplementation on lipid parameters in
hemodialysis patients. Am J Nephrol 1998;18:416–21.
50. Vlassopoulos D, Noussias C, Hadjipetrou A, Arvantis D, Logothetis E,
Magana P i sur. Long term effect of low molecular weight heparin on
serum lipids in hypertrigliceridemic chronic hemodialysis patients. J
Nephrol 1997;10:111–4.
51. Leu JG, Liou HH, Wu SC, Yang WC, Huang TP. Low molecular weight
heparin in diabetic and nondiabetic hypercholesterolemic patients receiving
long term hemodialysis. J Formos Med Assoc 1998;97:49–54.
52. Sperschneider H, Deppisch R, Beck W, Wolf H, Stein G. Impact of membrane
choice and blood flow pattern on coagulation and heparin requirement-potential
consequences on lipid concentrations. Nephrol Dial Transplant
1997;12(12):2638–46.
53. Mak RH. Effect of metabolic acidosis on hyperlipidemia in uremia. Pediatr
Nephrol 1999;13:891–3.
54. Bonnefont-Rousselot D, Lehman E, Jaudon MC, Delattre J, Perrone B,
Rechke JP. Blood oxidative stress and lipoprotein oxidizability in haemodialysis
patients: effect of the use of vitamin E-coated dialysis membrane.
Nephrol Dial Transplant 2000;15:2020–8.
55. Seres DS, Strein GW, Hashim S, Goldberg IJ, Levin NW. Improvement in
lipoprotein profiles during high flux dialysis. J Am Soc Nephrol 1993;3:
1409–15.
56. Josephson MA, Pellner SK, Dasisgupta A. Improved lipid profiles in
patient undergoing high flux dialysis. Am J Kidney Dis 1992;20:361–6.
57. Blankestijn PJ. Hemodialysis using high flux membranes improves lipid
profiles. Clin Nephrol 1994;42:48–51.
58. Goldberg IJ, Kaufman AM, Lavarias VA, Vann-Reyes T, Levin NW. High
flux dialysis membranes improve plasma lipoprotein profiles in patients
with end-stage renal disease. Nephrol Dial Transplant 1996;11:104–7.
59. Crawfor GA, Mahony JF, Stewart JH. Impaired lipoprotein lipase activation
by uraemic and posttransplant sera. Clin Sci 1981;60:73–80.
60. Fishbane S, Bucala R, Pereira B, Founds H, Vlassara H. Reduction of
plasma apolipoprotein-B by effective removal of circulating glycation
derivates in uremia. Kidney Int 1997;52:1645–50.
61. Makita Z, Bucala R, Rayfield EJ, Friedman EA, Kaufman AM, Korbet
SM i sur. Reactive glycosylation endproducts in diabetic uremia and treatment
of renal failure. Lancet 1994;343:1519–22.
62. Ingram AJ, Parbtani A, Churcill DN. Effects of two low-flux celulose
acetate dialysers on plasma lipids and lipoproteins – A cross-over trial.
Nephrol Dial Transplant 1998;13:1452–7.
63. Horkko S, Huttunen K, Laara E, Kervinen K, Kesaniemi YA. Effects of
three treatment modes on plasma lipids and lipoproteins in uraemic patients.
Ann Med 1994;26(4):271–82.
64. Avram MM, Goldwasser P, Burrell DE, Antignani A, Fein PA, Mittman
N. The uremic dyslipidemia: A cross-sectional and longitudinal study.
Am J Kidney Dis 1992;20(4):324–35.
65. Allegra V, Martimbianco L, Vasile A. Lipid and apolipoprotein patterns
during erythropoietin therapy: Roles of erythropoietin, route of administration,
and diet. Nephrol Dial Transplant 1997;12(5):924–32.
66. Prata MM, Madeira C, Vicente O, Miguel MJP. Lipid profile in haemodialysis
patients treated with recombinant human erythropoietin. Nephrol
Dial Transplan 1998;13(9):2345–7.
67. Turk Z, Mrzljak V, Turk N, Metelko Z. Changes of autoantibodies against
oxidatively modified low density lipoproteins during long-term LDL-
-apheresis. Diabetes Nutr Metab 1999;12(6):413–7.
80